Literature DB >> 22318237

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Jeffrey M Peters1, Yatrik M Shah, Frank J Gonzalez.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that are involved in regulating glucose and lipid homeostasis, inflammation, proliferation and differentiation. Although all of these functions might contribute to the influence of PPARs in carcinogenesis, there is a distinct need for a review of the literature and additional experimentation to determine the potential for targeting PPARs for cancer therapy and cancer chemoprevention. As PPAR agonists include drugs that are used for the treatment of metabolic diseases, a more complete understanding of the roles of PPARs in cancer will aid in determining any increased cancer risk for patients undergoing therapy with PPAR agonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318237      PMCID: PMC3322353          DOI: 10.1038/nrc3214

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  230 in total

Review 1.  Endogenous ligands for nuclear receptors: digging deeper.

Authors:  Michael Schupp; Mitchell A Lazar
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

2.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer.

Authors:  Lie Yang; Hong Zhang; Zong-Guang Zhou; Hui Yan; G Adell; Xiao-Feng Sun
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

4.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

Authors:  S S Palakurthi; H Aktas; L M Grubissich; R M Mortensen; J A Halperin
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

5.  In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.

Authors:  Naohiko Hamaguchi; Hironobu Hamada; Seigo Miyoshi; Kazunori Irifune; Ryoji Ito; Tatsuhiko Miyazaki; Jitsuo Higaki
Journal:  Cancer Sci       Date:  2010-09       Impact factor: 6.716

6.  Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis.

Authors:  Yatrik M Shah; Keiichirou Morimura; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-11-09       Impact factor: 4.052

7.  Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway.

Authors:  Chandan Sharma; Anamika Pradeep; Lucas Wong; Ajay Rana; Basabi Rana
Journal:  J Biol Chem       Date:  2004-06-09       Impact factor: 5.157

8.  Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.

Authors:  Toshiya Tanaka; Joji Yamamoto; Satoshi Iwasaki; Hiroshi Asaba; Hiroki Hamura; Yukio Ikeda; Mitsuhiro Watanabe; Kenta Magoori; Ryoichi X Ioka; Keisuke Tachibana; Yuichiro Watanabe; Yasutoshi Uchiyama; Koichi Sumi; Haruhisa Iguchi; Sadayoshi Ito; Takefumi Doi; Takao Hamakubo; Makoto Naito; Johan Auwerx; Masashi Yanagisawa; Tatsuhiko Kodama; Juro Sakai
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

9.  Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

Authors:  Matthew R Smith; Judith Manola; Donald S Kaufman; Daniel George; William K Oh; Elisabetta Mueller; Susan Slovin; Bruce Spiegelman; Eric Small; Philip W Kantoff
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

Review 10.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  S Mandard; M Müller; S Kersten
Journal:  Cell Mol Life Sci       Date:  2004-02       Impact factor: 9.261

View more
  184 in total

1.  APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production.

Authors:  Feng-Wei Wang; Chen-Hui Cao; Kai Han; Yong-Xiang Zhao; Mu-Yan Cai; Zhi-Cheng Xiang; Jia-Xing Zhang; Jie-Wei Chen; Li-Ping Zhong; Yong Huang; Su-Fang Zhou; Xiao-Han Jin; Xin-Yuan Guan; Rui-Hua Xu; Dan Xie
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

2.  Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancer.

Authors:  François Gaascht; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2015-11-17       Impact factor: 5.523

3.  Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression.

Authors:  Xiangsheng Zuo; Min Xu; Jiang Yu; Yuanqing Wu; Micheline J Moussalli; Ganiraju C Manyam; Sun Il Lee; Shoudan Liang; Mihai Gagea; Jeffrey S Morris; Russell R Broaddus; Imad Shureiqi
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

4.  Inhibition of tumorigenesis by peroxisome proliferator-activated receptor (PPAR)-dependent cell cycle blocks in human skin carcinoma cells.

Authors:  Michael G Borland; Ellen M Kehres; Christina Lee; Ashley L Wagner; Brooke E Shannon; Prajakta P Albrecht; Bokai Zhu; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2018-05-03       Impact factor: 4.221

5.  PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice.

Authors:  Tobias Gutting; Christian A Weber; Philip Weidner; Frank Herweck; Sarah Henn; Teresa Friedrich; Shuiping Yin; Julia Kzhyshkowska; Timo Gaiser; Klaus-Peter Janssen; Wolfgang Reindl; Matthias P A Ebert; Elke Burgermeister
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

Review 6.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

7.  Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

Authors:  Jordan Kardos; Shengjie Chai; Lisle E Mose; Sara R Selitsky; Bhavani Krishnan; Ryoichi Saito; Michael D Iglesia; Matthew I Milowsky; Joel S Parker; William Y Kim; Benjamin G Vincent
Journal:  JCI Insight       Date:  2016-03-17

8.  Hsp90 chaperones PPARγ and regulates differentiation and survival of 3T3-L1 adipocytes.

Authors:  M T Nguyen; P Csermely; C Sőti
Journal:  Cell Death Differ       Date:  2013-10-04       Impact factor: 15.828

9.  Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity.

Authors:  Pei-Li Yao; Jose L Morales; Bokai Zhu; Boo-Hyon Kang; Frank J Gonzalez; Jeffrey M Peters
Journal:  Mol Cancer Ther       Date:  2014-01-24       Impact factor: 6.261

10.  Targeting estrogen receptor-β for the prevention of nonmelanoma skin cancer.

Authors:  Pei-Li Yao; Frank J Gonzalez; Jeffrey M Peters
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.